Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Street Poller Media and The Boom of the Street Interview Ad Industry 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Toyota Global Sales Fall as China Demand Slumps 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Add as a preferred source on Google
LEXINGTON, Mass., April 04, 2018 -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on April 2, 2018 it issued inducement awards to five new employees.
These awards were made under T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted by the company’s Board of Directors on March 1, 2018 and provides for the granting of equity awards to new employees of T2 Biosystems. The inducement awards consist of options to purchase 49,000 shares of T2 Biosystems common stock and have a ten-year term. The exercise price of the options is $6.32, which was the per-share closing price of T2 Biosystems common stock on the Nasdaq Capital Market on April 2, 2018. The options vest over a four-year period, with 25% vesting on the first anniversary of the employee’s date of hire and the remainder vesting in equal monthly installments over the three years thereafter. The award was approved by the independent compensation committee of T2 Biosystems’ board of directors and was granted as an inducement material to the new employee entering into employment with T2 Biosystems in accordance with Nasdaq Marketplace Rule 5635(c)(4).
About T2 Biosystems
T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, improves patient care and reduces the cost of healthcare by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, and the T2Bacteria® Panel and are powered by the proprietary T2 Magnetic Resonance technology, or T2MR®. T2Bacteria Panel is commercially available in Europe and other countries that accept the CE Mark and is available for research use only in the U.S. For more information, please visit www.t2biosystems.com.
T2 Biosystems Media Contact:
Amy Phillips, Feinstein Kean Healthcare
[email protected]
412-327-9499
T2 Biosystems Investor Contact:
Chris Brinzey, Westwicke Partners
[email protected]
339-970-2843
